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Surrogate markers may help predict the effects of first-line treatment on survival. This metaregression analysis examines the
relationship between several surrogate markers and survival in women with advanced breast cancer after receiving first-line
combination anthracycline chemotherapy 5-fluorouracil, adriamycin and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin and
cyclophosphamide (FEC) . From a systematic literature review, we identified 42 randomised trials. The surrogate markers were
complete or partial tumour response, progressive disease and time to progression. The treatment effect on survival was quantified by
the hazard ratio. The treatment effect on each surrogate marker was quantified by the odds ratio (or ratio of median time to
progression). The relationship between survival and each surrogate marker was assessed by a weighted linear regression of the
hazard ratio against the odds ratio. There was a significant linear association between survival and complete or partial tumour
response (Po0.001, R
2¼34%), complete tumour response (P¼0.02, R
2¼12%), progressive disease (Po0.001, R
2¼38%) and time
to progression (Po0.0001, R
2¼56%); R
2 is the proportion of the variability in the treatment effect on survival that is explained by the
treatment effect on the surrogate marker. Time to progression may be a useful surrogate marker for predicting survival in women
receiving first-line anthracycline chemotherapy and could be used to estimate the survival benefit in future trials of first-line
chemotherapy compared to FAC or FEC. The other markers, tumour response and progressive disease, were less good.
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Survival time is the generally accepted outcome used to assess the
overall benefit of treatment for advanced breast cancer. However,
demonstration of a survival benefit following first-line chemo-
therapy can be obscured by the increasing use of effective second
and third-line chemotherapeutic agents. Surrogate markers, such
as tumour response, may help to predict the effects of first-line
treatment on survival. A’Hern et al, 1988 used the results of 50
randomised trials of chemotherapy in the treatment of breast
cancer and showed that there was a statistically significant
relationship between tumour response and survival. Such a
relationship has recently been shown in patients with advanced
colorectal cancer receiving first-line chemotherapy, though the
ability to predict survival for a given tumour response was not as
precise as expected (Buyse et al, 2000b). We here examine the
relationship between several surrogate markers (including tumour
response) and survival in women with advanced breast cancer after
receiving first-line combination 5-fluorouracil, adriamycin and
cyclophosphamide (FAC) or 5-fluorouracil, epirubicin and cyclo-
phosphamide (FEC) chemotherapy in clinical trials.
METHODS
Assessment of the relationship between survival and surrogate end
points is best done when based on data from randomised trials
(Buyse and Piedbois, 1996).
Data
In all, 42 randomised trials were identified from the published
literature (Medline 1966–2005) that compared two or more first-line
combination therapies in women with metastatic breast cancer. The
search criteria included the terms ‘breast’, ‘advanced or metastatic
or metastases’, ‘fluorouracil or 5-FU’, ‘cyclophosphamide’, ‘trial or
random*’ and ‘adriamycin or adriamicin or doxorubicin or
epirubicin or epidoxorubicin or anthracycline’. Trials were included
in the analyses if they met the following criteria:
(i) All women had metastatic disease (some trials included
women with recurrent breast cancer).
(ii) Women had received no previous chemotherapy for ad-
vanced disease.
(iii) If patients had previously been given adjuvant chemotherapy
they had to have had clear evidence of relapse and the original
therapy could not have included any anthracyclines
(iv) One of the treatment regimes included FAC or FEC.
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sThe surrogate markers included in this analysis were complete
or partial tumour response, disease progression and time to
progression. From each published report the following informa-
tion was obtained for each treatment group, found directly in the
results or by estimation from the illustrations:
  The proportion of patients with a complete and partial tumour
response
  The proportion of patients with progressive disease
  The median time to disease progression (months); taken as the
time from randomisation (or start of treatment) to the first sign
of progression or relapse. There were 9 trials that defined this as
the time from randomisation to progression, relapse or death.
These were not included in the main analysis but the results
are reported separately
  The median survival time (months); taken as the time from
randomisation (or start of treatment) to the date of death from
any cause
Statistical methods
The method used here is similar to that described by A’Hern
et al, 1988. We refer to the FAC or FEC treatment group as
Group 2 and the comparison treatments as Group 1. Briefly,
the following information (illustrated for complete response)
Table 1 Selected characteristics of the trials used in the analysis
Treatment arms
a
Trial (first author
& reference) Country
Year of patient
recruitment
b Group 1 Group 2
No. of patients
randomised
Muss et al (1978) USA 1976–1976 FMC+VP FAC+VP 175
Fritze et al (1982) Germany 1975 FAC+VM+C. parvum FAC+VM 156
Smalley et al (1983) USA 1974–1977 FMC+VP FAC 362
Steiner et al (1983) USA 1977–1980 FAC+MV FAC+M 119
Tormey et al (1984) USA 1974– (a) FMC+VPc FAC+VP 396
(b) FMC+VPd
Vogel et al (1984) USA o1982 FAC+VM, Leucovorin, Cytosine arabinside FAC 187
Boccardo et al (1985) Italy 1978–1982 FAC+Tamoxifen FAC+MV 81
Cummings et al (1985) USA 1978–1979 FMC+P FAC 177
Carpenter et al (1986) USA 1978–1982 FAC+Levamisole FAC 105
Aisner et al (1987) USA 1976–1980 (a) FMC FAC 432
(b) FAC+VP
Falkson et al (1987) USA, S. Africa 1968–1983 FAC+oophorectomy FAC 86
Hortobagyi et al (1987a) USA 1978–1981 High dose FAC+protected environment Low dose
FAC+ambulatory care
63
Hortobagyi et al (1987b) USA 1979–1980 FAC+vaccine FAC 133
Bennett et al (1988) USA 1983–1985 FNC FAC 333
French Epirubicin Study Group (1988) France 1982–1984 FEC FAC 263
Lopez et al (1989) Italy 1983–1985 FEC FAC 102
Falkson et al (1991) (B122) USA, S. Africa 1972– FMC FAC 78
Falkson et al (1991) (B141) USA 1974– FMC+AV, dibromodulcitol FAC 94
French Epirubicin Study Group (1991) France o1990 (a) FEC (75mg/m2)e FEC (50mg/m2)e 412
(b) E (75mg/m2)e
Falkson et al (1992) S. Africa o1992 mitomycin C+PA FAC 34
Speyer et al (1992) USA 1984–1989 ICRF-187+ FAC FAC 150
Ejlertsen et al (1993) Denmark 1986–1989 FEC 18 months FEC 6 months 359
Paridaens et al (1993) Belgium 1983–1987 FAC+ ethinylestradiol FAC 165
Pouillart et al (1994) France 1983–1984 FNC FAC 142
Alonso et al (1995) Spain 1988–1991 FNC FAC 100
Pavesi et al (1995) Italy 1987–1989 FNC FEC 152
Pierga et al (1995) France 1990–1993 FAC (15mg/m2)e FAC (50mg/m2)e 258
Conte et al (1996) Italy 1985–1990 FEC+D FEC 258
Pfeiffer et al (1996) Denmark 1985 FEC+Concurrent Tamoxifen FEC+Sequential Tamoxifen 273
Stewart et al (1997) Canada 1982–1988 FNC FAC 249
Esteban et al (1999) Spain 1987–1993 FNC FEC 151
French Epirubicin Study Group (2000) France 1987–1994 FEC (100mg/m2)e then FEC (50mg/m2)e FEC (75mg/m2)e 417
FEC (100mg/m2)e
Pacini et al (2000) Italy 1991–1996 EM7lonidamine FEC7lonidamine 326
Riccardi et al (2000) Italy 1995–1997 FEC (120mg/m2)e FEC (60mg/m2)e 74
Sledge et al (2000) USA 1988–1992 FAC+tamoxifen, fluoxymesterone FAC 231
Ackland et al (2001) Australia 1990–1992 FMC FEC 460
Hori et al (2001) Japan 1993–1996 Doxifluridine, C, ‘PA’ FAC+‘PA’ 99
Jassem et al (2001) E. Europe,
Israel, Russia
o2000 A, Paclitaxel FAC 267
Mackey et al (2002) USA 1998–1999 Docetaxel,AC FAC 484
Heidemann et al (2002) Germany 1992–1997 N FEC 260
Parnes et al (2003) USA 1991–1995 FAC+leucovorin FAC 241
Zielinski et al (2005) International 1999–2002 Gemcitabine, Paclitaxel, E FEC 259
aF (5-fluorouracil); A (adriamycin/doxorubicin); C (cyclophosphamide); E (epirubicin); M (methotrexate); V (vincristine); P (prednisone); N (Novantrone/mitoxantrone); ‘PA’
(medroxyprogesterone acetate); D (diethulstillbestrol).
bIf not reported, it is taken to be the year before the article was published.
cTherapy given continuously.
dTherapy given
intermittently.
eThe dose of epirubicin or doxorubicin is given in brackets.
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swas obtained for each trial and for tumour response and
progressive disease:
The odds ratio of having a complete response in Group 1
compared to Group 2 is given by (A D)/(B C), but after adding
0.5 to each of the four terms to allow for groups with zero events.
These ratios can be used to describe the treatment effect on the
surrogate marker. The treatment effect on time to progression
was estimated as the median time to progression in Group 1
divided by the median time in Group 2.
The hazard ratio was taken as the median survival time in
Group 1 divided by the median time in Group 2, assuming that
survival follows an exponential distribution. This is referred to as
the treatment effect on survival.
The relationship between the treatment effect on the surrogate
marker (odds ratio) and the treatment effect on survival (hazard
ratio) was examined using a linear regression, both on a log scale
and weighted by the inverse of the variance of the odds ratio.
For the regression of survival against time to progression, the
number of patients in the study was used as weights. To avoid
spurious associations resulting from forcing the regression
through the origin (where no treatment effect on the surrogate
marker indicates no treatment effect on survival), all regressions
contained an intercept term and were of the form log10 survival
ratio¼aþb log10 odds ratio.
From each regression model, the coefficient of determination
(R
2) was obtained; this is the proportion of the variability in the
treatment effect on survival that is explained by the treatment
effect on the surrogate marker.
It is realised that the method of assessment of tumour response
has varied over time and this could affect the proportion of
patients with a complete or partial tumour response. However,
because the same method of assessment was used for all treatment
groups in each trial, it is likely that the odds ratio (which is based
on comparing two groups) would not be greatly affected.
RESULTS
The 42 randomised trials (Table 1) were based on 9163 women
and 46 estimates of hazard ratio. In most trials the treat-
ment regimens that were compared to FAC or FEC resulted in a
reduction in the proportion of patients with complete or partial
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Treatment effect on having a complete or partial tumour response
0.3 0.2 0.1 0.4 0.5 1 2 3
Treatment effect on having a complete tumour response
0.3 0.2 0.4 0.5 1 2 3 4 5 6
Treatment effect on having progressive disease
0.6 0.5 0.7 0.8 0.9 1.5 12
Treatment effect on time to progression
AB
CD
Figure 1 The relationship between the treatment effect on median survival time and each of the four surrogate markers. The regression lines are
as follows, with the corresponding P-value, coefficient of determination (R
2) and standard error of the regression coefficient (s.e.) in brackets: (A) Log10
hazard ratio¼ 0.0081þ0.2796 log10 odds ratio for complete/partial response (Po0.0001, R
2¼34%, s.e.¼0.0590), (B) Log10 hazard
ratio¼ 0.0097þ0.1266 log10 odds ratio for complete response (P¼0.02, R
2¼12%, s.e.¼0.0521), (C) Log10 hazard ratio¼0.0015–0.1781 log10
odds ratio for progressive disease (Po0.0001, R
2¼38%, s.e.¼0.0380), (D) Log10 hazard ratio¼0.0135þ0.5082 log10 ratio of median time to
progression (Po0.001, R
2¼56%, s.e.¼0.0928). The size of the symbols is proportional to the inverse of the variance (the weight). For time to progression
the size is proportional to the number of patients in the trial.
Treatment
Number of
evaluable
patients
Number of
patients with
a complete
response
Number of
patients without
complete
response
Group 1 N1 A C¼N1 A
Group 2 (FAC or FEC) N2 B D¼N2 B
First-line combination anthracycline chemotherapy
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stumour responses, an increase in progressive disease and shorter
median survival times.
Figure 1 shows the relationship between the treatment effect on
the median survival time (survival ratio) and the treatment effect
on tumour response and disease progression (odds ratio). There
was a statistically significant linear association between survival
and complete or partial tumour response (P-value o0.0001); 34%
of the variability in the treatment effect on survival can be
explained by the treatment effect on tumour response. When the
data are restricted to only those patients with a complete response,
there was still evidence of a linear association with survival
(P-value 0.02), though only a small proportion of the variability
could be explained (R
2¼12%). There was also a relationship
with progressive disease (P-valueo0.0001, R
2¼38%) and time to
progression (P-value o0.0001, R
2¼56%); the latter suggesting
that a moderately high proportion of the variability in the
treatment effect on survival can be explained by the treatment
effect on time to progression. The results on time to progression
were similar in the 9 trials that included death as an event
(regression coefficient 0.4817, P-value¼0.017, R
2¼58%).
There is a possibility that second-line therapies may have
obscured the relationships between survival and the surrogate
markers. To assess this effect we compared the regression analyses
in trials that recruited patients before 1990, when second-line
therapies would have been uncommon, to those that recruited in
1990 or later. Table 2 shows the results from this analysis and those
from all trials; they are consistent with each other.
Table 3 shows hypothetical examples of two treatments and the
predicted effects on survival using the regression equations in
F i g u r e1 .F o re x a m p l e ,i fo n et r e a t m e n t( A )h a dar e s p o n s er a t eo f
30% and a median survival time of 20 months and another (treatment
B) was expected to double the response rate to 60%, the estimated
median survival using treatment B would be 28 months; an increase in
survival of 8 months (Appendix A provides details of the calculation).
Similarly, a doubling of the median time to progression was associated
with a median survival time that could be 9 months greater.
DISCUSSION
These results suggest that tumour response and progressive
disease are both associated with survival in women receiving
first-line FAC or FEC chemotherapy for advanced breast cancer,
but the best surrogate marker is time to progression. The strength
of the association was only modest for tumour response (R
2¼
34%) and progressive disease (R
2¼38%), but stronger for time to
progression (R
2¼56%).
The conclusion for tumour response is similar to that reported
by A’Hern et al, 1988 whose analysis was based on all chemo-
therapy trials published by 1986. In that analysis an estimated 37%
of the variability in survival was explained by variation in tumour
response (compared to our estimate of 34%). Our analysis differs
to that by A’Hern et al, 1988 for several reasons – only 10 of the 42
trials in our analysis could have been included; we only included
trials that included FAC/FEC first-line therapies; several surrogate
markers were assessed here; and we used a different model to
quantify the association between survival and each surrogate
marker (we used linear relationships that were not forced to go
through the origin thereby avoiding possible spurious associations
– A’Hern et al, 1988 used a quadratic model that was forced
through the origin).
The appeal of a perfect surrogate marker is that if it can be
measured earlier than a ‘true’ end point (such as survival) then a
trial would require less time spent on following-up patients before
a conclusion can be made about the treatment being tested.
Furthermore, if one is interested in assessing a first-line therapy
then the effect on survival may be obscured if patients are given
second- and third-line therapies; the advantage of using a
surrogate marker is that it could be measured before these
subsequent therapies are administered. Several investigators have
discussed various approaches to determine the usefulness of
proposed surrogates. Buyse and Molenberghs, 1998 introduce the
concept of ‘relative effect’. This compares the treatment effect on
survival with the treatment effect on the surrogate marker. The
relative effect is simply the slope of the regression line from a
regression analysis. A perfect surrogate would have a relative effect
of 1. In our analyses the relative effects were small for complete/
partial response (0.28) and progressive disease (0.18) but greater
for time to progression (0.51). However, a marker could still
be useful as a surrogate if it predicts worthwhile changes in the
true end point, such as survival. Our results indicate that this may
be so (Table 3).
Buyse et al (2000a) suggest evaluating surrogacy by estimating
two coefficients of determination; R2
trial based on data from the
Table 2 Comparison of regression analyses in trials that recruited
patients before 1990 (when second-line therapies were not commonly
used) and after 1990
Surrogate marker;
last year of patient
recruitment
Number
of
studies
Slope from
regression
line R
2a
P-value from
regression
analysis
Complete/partial response
o1990 29 0.28 26% 0.004
1990+ 17 0.24 41% 0.005
All 46 0.28 34% o0.001
Complete response
o1990 29 0.09 5% 0.24
1990+ 16 0.16 36% 0.01
All 45 0.13 12% 0.02
Progressive disease
o1990 21  0.26 39% 0.002
1990+ 17  0.14 45% 0.003
All 38  0.18 38% o0.0001
Time to progression
o1990 17 0.58 67% o0.0001
1990+ 9 0.40 41% 0.06
All 26 0.51 56% o0.0001
aR
2 is the coefficient of determination (the percentage of variability in survival
explained by the surrogate marker). A test comparing the regression slopes (o1990
vs 1990+) yielded P-values that were not statistically significant – complete/partial
response P¼0.37; complete response P¼0.26; progressive disease P¼0.06; time to
progression P¼0.15.
Table 3 Two hypothetical treatments (A and B)
Percentage
of patients
with a
complete/
partial
tumour
response
Median
survival,
months
(95% CI)
Percentage
of patients
with
progressive
disease
Median
survival,
months
(95% CI)
Median
time to
progression
(months)
Median
survival,
months
(95% CI)
On treatment A On treatment A On treatment A
30 20 12 20 10 20
On treatment B On treatment B On treatment B
40 22 (20–24) 10 21 (20–22) 12 23 (21–24)
50 25 (22–28) 8 22 (20–23) 16 26 (23–29)
60 28 (24–33) 6 23 (21–25) 20 29 (25–34)
The estimated effect on survival using treatment B compared to A based on arbitrary
estimates of tumour response and disease progression, and the regression analyses in
Figure 1. CI, confidence interval (based on the 95% CI of the predicted mean value in
the regression analysis).
First-line combination anthracycline chemotherapy
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strials and the R2
indiv based on individual patients. A marker would
be called ‘trial-level’ valid if R2
trial is close to one and ‘individual-
level’ valid if R2
indiv is close to one. The latter would indicate the
ability for a marker to predict survival for an individual patient.
Furthermore, a large R2
indiv indicates that the surrogate is causally
linked to the true end point, an observation that confirms that a
surrogate is highly effective. In an example of treating advanced
ovarian cancer (Buyse et al, 2000a) individual patient data were
available so both R
2 values could be estimated. Survival was the
true end point and time to progression was the proposed surrogate
marker. They found that R2
trial ¼0.94 and R2
indiv ¼0.89, both
sufficiently high to conclude that time to progression could be
used as a surrogate. In our analyses we did not have individual
patient data so were unable to estimate R2
indiv. Our estimates for
R2
trial were only modest for tumour response (34%) and progressive
disease (38%) but greater for time to progression (56%).
There are limitations to our analysis. First, although this
analysis was restricted to randomised trials (thereby minimising
some biases associated with similar analyses of surrogate markers
(Buyse and Piedbois, 1996), it was based on performing regres-
sions using summary data, namely odds ratios and survival ratios.
The ability to predict survival from a surrogate marker for an
individual patient will therefore be limited (Buyse and Piedbois,
1996). Analyses of these trials using individual patient data would
provide more precise estimates of the predictive ability of these
markers on survival. Second, it was not possible to assess the effect
of second-line therapies in patients whose disease progressed
during the course of the trials; such therapies may also have had an
affect on survival. For instance, a trial by Nabholtz et al (1999)
showed that patients with advanced breast cancer may benefit in
terms of survival from more effective second-line therapy. All
patients in this trial had already received first-line anthracycline
chemotherapy for metastatic cancer and were randomised to
receive either docetaxel or mitomycin plus vinblastine; survival
was longer in the docetaxel group (11.4 vs 8.7 months). However,
our analysis of trials that recruited patients before 1990, when
second-line therapies were less likely to have been used, gave
similar results to those published after 1990 (Table 2).
Despite these limitations the results may be useful when
determining the efficacy of first-line treatments for advanced
breast cancer that use anthracyclines. With the increasing use of
effective second and third-line chemotherapy in breast cancer this
type of analysis offers a means of comparing new first-line
chemotherapy treatments to first-line anthracycline combination
therapies without the effect being masked by second or third line
therapies.
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Appendix A
Example of estimating the effect on survival using two
hypothetical treatments
If treatment A has a response rate of 30% and a median
survival time of 20 months and treatment B has a response
rate of 60%, the estimated survival time for B is 29 months,
obtained as follows:
(i) The odds ratio for response (Treatment B compared to
Treatment A) is:
0:60 ð1   0:30Þ
0:30 ð1   0:60Þ
¼ 3:5
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regression equation in Figure 1 :
log10 hazard ratio¼ 0.0081þ0.2796 log10 [odds ratio for
complete/partial response]
log10 hazard ratio¼ 0.0081þ0.2796 log10 [3.5]
log10 hazard ratio¼0.1440
(iii) The ratio of the log survival ratios is:
log10
mediansurvivalinTreatmentB
mediansurvivalinTreatmentA

¼ 0:1440
log10
mediansurvivalinTreatmentB
20months

¼ 0:1440
The estimated median survival in Treatment B is: 20 10
0.1440,
which is 28 months.
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